Form 4: Indaptus Therapeutics CEO Granted Stock Options
SEC Form 4
Jeffrey Meckler, CEO of Indaptus Therapeutics, receives stock options for 75,000 shares.
Summary
- On October 9, 2024, Jeffrey A. Meckler, CEO and Director of Indaptus Therapeutics, Inc., was granted stock options for 75,000 shares.
- The exercise price of the stock options is $1.105.
- The options vest fully on April 9, 2026, contingent upon Meckler's continued service to the company.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.
Positives
- The granting of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with those of shareholders. This grant is a standard form of compensation for a CEO in a publicly traded company.
Comparison to Industry Standards
- Stock option grants are a common form of executive compensation in the biotech industry.
- Companies like Amgen, Gilead, and Biogen routinely grant stock options to their executives as part of their overall compensation packages.
- The vesting schedule of these options, typically over a period of 2-4 years, is also standard practice.
Stakeholder Impact
- Shareholders may view this as a positive incentive for the CEO.
- Employees may see this as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 10/09/2024 | Date of the stock option grant. |
| 04/09/2026 | Date the stock options fully vest. |
| 10/09/2034 | Expiration date of the stock options. |
| 10/10/2024 | Date of the Form 4 filing. |
Keywords
stock options, Indaptus Therapeutics, CEO, Jeffrey Meckler, INDP, equity compensation, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.